KAI Y WONG

Allopathic & Osteopathic Physicians|Family Medicine MONTEREY PARK, CA NPI 1376656967

General Payments — all program years on this page

$24,064.55

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 309
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $2,026.65 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $2,013.1117
Travel and Lodging $13.541

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $622.155
Gilead Sciences, Inc. $528.355
Phathom Pharmaceuticals, Inc. $370.323
GlaxoSmithKline, LLC. $245.642
Lilly USA, LLC $135.652
Lexicon Pharmaceuticals, Inc. $124.541

By program year

Program yearAmountRecords
2018 $6,819.3784
2019 $5,269.7167
2020 $1,784.0232
2021 $4,072.1955
2022 $2,002.6624
2023 $2,089.9529
2024 $2,026.6518

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1081708095 Lexicon Pharmaceuticals, Inc. $124.54 09/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105320880 AstraZeneca Pharmaceuticals LP $125.00 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105363573 AstraZeneca Pharmaceuticals LP $124.99 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105488639 AstraZeneca Pharmaceuticals LP $125.00 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105653352 AstraZeneca Pharmaceuticals LP $123.61 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105813505 AstraZeneca Pharmaceuticals LP $123.55 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116130582 GlaxoSmithKline, LLC. $121.83 04/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116485091 GlaxoSmithKline, LLC. $123.81 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133747722 Gilead Sciences, Inc. $125.00 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133747724 Gilead Sciences, Inc. $125.00 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133747726 Gilead Sciences, Inc. $149.97 04/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133747728 Gilead Sciences, Inc. $3.38 10/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133747730 Gilead Sciences, Inc. $125.00 11/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135088325 Lilly USA, LLC $122.11 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135116341 Lilly USA, LLC $13.54 02/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1151140331 Phathom Pharmaceuticals, Inc. $135.00 04/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151140333 Phathom Pharmaceuticals, Inc. $90.00 04/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151140335 Phathom Pharmaceuticals, Inc. $145.32 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.